Company Overview and News
Chicago, IL – March 21, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Cerner Corporation (CERN - Free Report) , AmerisourceBergen Corporation (ABC - Free Report) , Fresenius Medical Care (FMS - Free Report) and Olympus Corp.
Emerging market investment has taken a backseat of late, thanks to the nonstop blows to the economy. The lingering geopolitical tension in Gulf, debt and policy related hazards in Latin America or the missile tests in North Korea have led stock investors to reconsider their outlay in these markets, earlier proclaimed to offer better growth opportunities than the United States. Going by the MSCI Emerging Markets Index, the last five-year annualized growth rate was just 5.
Chicago, IL – March 1, 2018 – Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 2, including Abbott (ABT - Free Report) , Becton, Dickinson and Co. (BDX - Free Report) , Stryker (SYK - Free Report) , Varian Medical (VAR - Free Report) and Boston Scientific (BSX - Free Report) .
In the past few years, the U.S. medical device market has undergone substantial transformation. While there are a number of regulatory and financial issues unlikely to be resolved soon, powerful long-term tailwinds, including mergers & acquisitions (M&As), emerging market expansion, positive demographic trends and product innovation, have been contributing to the continued growth of the sector.
Chicago, IL – Feb 28, 2018 – Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 1, including Johnson & Johnson (JNJ - Free Report) , Medtronic (MDT - Free Report) , Covidien and Smith & Nephew (SNN - Free Report) , Abbott Labs (ABT - Free Report) and Boston Scientific (BSX - Free Report) .
The Q4 earnings season is approaching its end with more than 80% of the S&P 500 companies having released their quarterly earnings. Most of the companies have incurred big one-time charges related to the change in tax law this time around. The gap between adjusted operating earnings and reported earnings is in fact the widest in recent years. The MedTech space is also not immune to the trend.
Chicago, IL – December 26, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Bio-Rad Laboratories, Inc. (BIO - Free Report) , Mazor Robotics Ltd. (MZOR - Free Report) , Tactile Systems Technology, Inc. (TCMD - Free Report) , Eli Lilly and Company (LLY - Free Report) and DexCom, Inc.
The medical devices industry, which was once acclaimed for its high-paying jobs and research and development opportunities, has been subject to the much controversial 2.3% medical device excise tax. The MedTech fraternity is leaving no stone unturned to permanently do away with the dreadful tax — but has not been able to.
Ecolab Inc. (ECL - Free Report) , Techstars and the world’s largest private agricultural company, Cargill, recently announced the launch of a accelerator program in Minnesota. The program is called ‘Farm to Fork Accelerator’.
Chicago, IL – November 28, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include IDEXX Laboratories, Inc. (IDXX - Free Report) , Luminex Corporation (LMNX - Free Report) , Masimo Corporation (MASI - Free Report) , Align Technology Inc.
The latest $1.5-trillion tax reform plan has been a landmark achievement for President Trump. As usual, in its initial stage, the nation gave mixed reactions on the controversial bill. While a few Americans slammed the new plan as a ‘job killer,' others found it to be ‘an excellent opportunity to fix a broken tax code.'
Chicago, IL – October 26, 2017 – Today, Zacks Equity Research discusses the MedTech, including Johnson & Johnson (JNJ - Free Report) , Abbott Labs (ABT - Free Report) , Medtronic (MDT - Free Report) and Boston Scientific (BSX - Free Report) .
The political gridlock over the pullback of the Affordable Care Act or Obamacare has been making headlines in the MedTech space. The MedTech space received a sudden jolt recently when White House pulled the plug on Obamacare subsidies that reduce health care costs for Americans with low incomes. There are concerns that the final ‘Trump-care plan’ will still include the MedTech tax repeal in its agenda.
The MedTech space received a sudden jolt on late night Thursday when White House pulled the plug on Obamacare subsidies that reduce health care costs for Americans with low incomes. This comes as no surprise for the lukewarm response to its replacement, The American Health Care Act (AHCA), has forced Republicans to continue to seek new avenues. In a bid to save its face, the Trump administration attempted a “skinny" repeal bill along with a Graham-Cassidy bill, which failed to make any headway in the senate.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...